Elixxer Financials
| ELXR Stock | CAD 1.15 0.00 0.00% |
Elixxer | Select Account or Indicator |
Understanding current and past Elixxer Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Elixxer's financial statements are interrelated, with each one affecting the others. For example, an increase in Elixxer's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Elixxer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elixxer. Check Elixxer's Beneish M Score to see the likelihood of Elixxer's management manipulating its earnings.
Elixxer Stock Summary
Elixxer competes with Titanium Transportation, Precious Metals, Tincorp Metals, Andean Precious, and Canso Select. Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. ELIXXER is traded on Commodity Exchange in Exotistan.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | Canada Stock View All |
| Exchange | TSX Venture Exchange |
| ISIN | CA28660W2004 |
| Business Address | 1100 Boulevard Rene- |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.elixxer.com |
| Phone | 514 788 1499 |
| Currency | CAD - Canadian Dollar |
You should never invest in Elixxer without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Elixxer Stock, because this is throwing your money away. Analyzing the key information contained in Elixxer's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Elixxer Key Financial Ratios
There are many critical financial ratios that Elixxer's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Elixxer reports annually and quarterly.| Gross Profit | 42.41 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (4.01 M) | ||||
| Total Asset | 2.81 M | ||||
| Retained Earnings | (84.51 M) |
Elixxer Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Retained Earnings | (62.7M) | (66.3M) | (80.5M) | (84.5M) | (76.1M) | (79.9M) | |
| Accounts Payable | 2.3M | 1.5M | 1.9M | 2.9M | 3.4M | 1.8M | |
| Net Receivables | 211.1K | 1.2M | 222.6K | 111.2K | 127.9K | 121.5K | |
| Total Current Assets | 2.3M | 13.7M | 2.5M | 31.1K | 28.0K | 26.6K |
Elixxer Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 2.1M | 1.7M | 2.5M | 2.6M | 3.0M | 1.5M | |
| Net Income Applicable To Common Shares | (18.9M) | (9.8M) | (3.7M) | (14.2M) | (16.3M) | (17.1M) |
Elixxer Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | 1.1M | 2.2M | 2.3M | 2.4M | 2.7M | 2.8M | |
| Change In Cash | 1.2M | (1.8M) | (236.3K) | (45.1K) | (40.6K) | (38.6K) | |
| Net Income | (9.8M) | (3.7M) | (14.2M) | (4.0M) | (4.6M) | (4.8M) | |
| End Period Cash Flow | 2.1M | 301.8K | 65.4K | 20.3K | 18.3K | 17.4K | |
| Net Borrowings | 4.1M | 2.7M | 161.6K | 1.0M | 938.7K | 1.7M | |
| Depreciation | 2.0K | 2.0K | 2.0K | 494.0 | 568.1 | 539.69 |
Elixxer Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Elixxer's current stock value. Our valuation model uses many indicators to compare Elixxer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elixxer competition to find correlations between indicators driving Elixxer's intrinsic value. More Info.Elixxer is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Elixxer's earnings, one of the primary drivers of an investment's value.Elixxer Systematic Risk
Elixxer's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Elixxer volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Elixxer correlated with the market. If Beta is less than 0 Elixxer generally moves in the opposite direction as compared to the market. If Elixxer Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Elixxer is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Elixxer is generally in the same direction as the market. If Beta > 1 Elixxer moves generally in the same direction as, but more than the movement of the benchmark.
Elixxer Total Assets Over Time
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.